Loading clinical trials...
Loading clinical trials...
A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen
Conditions
Interventions
Aflibercept
Placebo
Locations
37
China
Investigational Site Number 156003
Beijing, China
Investigational Site Number 156001
Beijing, China
Investigational Site Number 156002
Beijing, China
Investigational Site Number 156004
Beijing, China
Investigational Site Number 156016
Chengdu, China
Investigational Site Number 156020
Chongqing, China
Start Date
July 1, 2012
Primary Completion Date
October 1, 2014
Completion Date
July 1, 2015
Last Updated
October 18, 2016
NCT05759728
NCT07328087
NCT07213570
NCT06889610
NCT05200442
NCT05057052
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions